Novartis Gene Therapies
NEWS
According to a BioSpace survey, almost 70% of respondents are likely to look for a new job in the 12 months. The question is, why? Of those planning to look for a new job, 54% said they wanted new challenges and 42% said they wanted more rewarding opportunities. How about you? Are you ready to look for a job with more challenges and rewarding opportunities?
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.
SMA is a severe neuromuscular disease caused by a mutation in the SMN1 gene, which codes for SMN, a protein necessary for motor neuron function.
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don’t stop looking. You never know what may come your way!
Just as Novartis and AveXis’ gene therapy, Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy (SMA) is progressing toward approval, a second patient death was reported.
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
AveXis, a Novartis company, announced interim data from its Phase III STR1VE clinical trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
The Novartis subsidiary said it plans to offer jobs to the 150 employees currently working at the Colorado facility and add additional headcount there in the future.
JOBS
IN THE PRESS